Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KCNB1 | Q14721 | 2/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476281 | 1.00 | MEN1 (0.39) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL4466954 | 0.85 | TP53 (0.48) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL4457384 | 0.84 | TSHR (0.41) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL4465442 | 0.84 | TSHR (0.41) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL4471589 | 0.80 | PDE4B (0.38) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL4462080 | 0.80 | PDE4B (0.38) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL4458570 | 0.77 | TP53 (0.49) | MEN1KMT2ALMNAALDH1A1TP53 | |
| SCHEMBL27702523 | 0.75 | TP53 (0.49) | MEN1KMT2ALMNAALDH1A1TP53 | |
| SCHEMBL4472346 | 0.75 | TP53 (0.47) | TP53TSHRSMN1; SMN2 | |
| SCHEMBL4457771 | 0.75 | SMN1; SMN2 (0.53) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | claimed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| CN-101166737-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | PDE4A, PDE4B, PDE12 | MEN1 865/4885KMT2A 1797/4885MAPT 3363/4885 |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE5A | MEN1 2305/4885KMT2A 1916/4885MAPT 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.